Safety, tolerability and immunogenicity of an active anti‐Aβ40 vaccine (ABvac40) in patients with amnestic mild cognitive impairment (A‐MCI) or very mild alzheimer’s disease (VM‐AD): A randomized, double‐blind, placebo‐controlled, phase II trial: Human/Human trials: Anti‐amyloid